| Literature DB >> 33794192 |
Hyelim Cho1, Qiong Shen1, Lydia H Zhang2, Mikiko Okumura2, Akinori Kawakami3, Jessi Ambrose1, Frederic Sigoillot1, Howard R Miller1, Scott Gleim1, Amanda Cobos-Correa4, Ying Wang4, Philippe Piechon4, Guglielmo Roma4, Fabian Eggimann4, Charles Moore4, Peter Aspesi1, Felipa A Mapa1, Heather Burks1, Nathan T Ross1, Philipp Krastel4, Marc Hild1, Thomas J Maimone2, David E Fisher3, Daniel K Nomura5, John A Tallarico6, Stephen M Canham6, Jeremy L Jenkins7, William C Forrester8.
Abstract
Three limonoid natural products with selective anti-proliferative activity against BRAF(V600E) and NRAS(Q61K)-mutation-dependent melanoma cell lines were identified. Differential transcriptome analysis revealed dependency of compound activity on expression of the mitochondrial cytochrome P450 oxidase CYP27A1, a transcriptional target of melanogenesis-associated transcription factor (MITF). We determined that CYP27A1 activity is necessary for the generation of a reactive metabolite that proceeds to inhibit cellular proliferation. A genome-wide small interfering RNA screen in combination with chemical proteomics experiments revealed gene-drug functional epistasis, suggesting that these compounds target mitochondrial biogenesis and inhibit tumor bioenergetics through a covalent mechanism. Our work suggests a strategy for melanoma-specific targeting by exploiting the expression of MITF target gene CYP27A1 and inhibiting mitochondrial oxidative phosphorylation in BRAF mutant melanomas.Entities:
Keywords: BRAF; CYP27A1; MITF; cancer metabolism; melanoma; mitochondrial complex I; natural products; oncology; oxidative phosphorylation; prodrug
Mesh:
Substances:
Year: 2021 PMID: 33794192 PMCID: PMC8481390 DOI: 10.1016/j.chembiol.2021.03.004
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 9.039